Answers are grounded in this paper and cite their sources.
Correction notes an error in imagery while discussing disulfiram's impact on sorafenib efficacy in hepatocellular carcinoma, highlighting implications for treatment.
H, Cai L, Zhang L, Tanabe KK and Wang X (2022) Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram. Front. Oncol. 12:913736. doi: 10.3389/fonc.2022.913736In the published article, there was an error in Figure 2E as published. Some of the sphere images were unintentionally duplicated during the preparation process. The corrected Figure 2E and its caption appear below.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: